Equities Analysts Set Expectations for RNTX FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 earnings forecast for Rein Therapeutics to a loss of $0.47 per share from a projected loss of $0.53, maintaining a “Buy” rating.
• Rein Therapeutics reported a quarterly loss of $0.10 per share, beating analyst expectations for a $0.27 loss by $0.17 per share.
• Analyst sentiment is mixed, with two Buy ratings, one Hold and one Sell; the stock carries an average “Hold” rating and a $6.00 consensus price target, while shares recently traded near $0.79.

Rein Therapeutics Inc. (NASDAQ:RNTX - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings estimates for Rein Therapeutics in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.47) per share for the year, up from their previous forecast of ($0.53). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Rein Therapeutics' current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Rein Therapeutics' Q4 2026 earnings at ($0.15) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at ($0.58) EPS.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.17.

Several other analysts also recently issued reports on RNTX. Weiss Ratings raised Rein Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 3rd. Wall Street Zen raised Rein Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 6th. Finally, Maxim Group began coverage on Rein Therapeutics in a report on Monday, July 20th. They set a "buy" rating and a $4.00 price objective for the company. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $6.00.

Rein Therapeutics Trading Up 2.8%

Shares of NASDAQ RNTX opened at $0.79 on Thursday. The firm has a market cap of $68.33 million, a PE ratio of -0.46 and a beta of 1.39. Rein Therapeutics has a 1-year low of $0.69 and a 1-year high of $2.18. The company has a fifty day moving average price of $0.88 and a 200 day moving average price of $1.12.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new stake in Rein Therapeutics in the 3rd quarter valued at $35,000. HRT Financial LP acquired a new position in shares of Rein Therapeutics during the 4th quarter worth about $38,000. Chicago Partners Investment Group LLC grew its holdings in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company's stock valued at $53,000 after acquiring an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in shares of Rein Therapeutics in the 2nd quarter valued at about $68,000. Finally, Jane Street Group LLC acquired a new stake in shares of Rein Therapeutics in the fourth quarter valued at about $72,000. Institutional investors own 90.89% of the company's stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source